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The precise mechanism of neutralization of viruses by antibody is at present 
only poorly understood.  In most instances it has been shown that neutralizing 
antibodies interact with surface '~capsid" polypeptides (1-8). Examples of specific 
capsid  peptides that  have  been  shown to  be responsible  for the  induction  of 
neutralizing  antibody include hexon and fiber polypeptides for adenovirus  (7, 
8)  and  hemagglutinin  for  influenza  (6).  In  general,  these  results  have  been 
obtained by purifying individual viral proteins or a group of proteins and then 
preparing  antisera  to them  (1-5,  7,  8).  For reovirus,  we have  examined  this 
question using a  genetic approach. 
Reovirus contains 10 segments of double-stranded RNA (dsRNA)  ~ surrounded 
by a  double  capsid  shell;  the  segments  are  named  according  to  size classes: 
three  large  segments  (L1,  L2,  and  L3) with  mol wt of -2.3-2.5  ×  10  ~,  three 
medium segments  (M1,  M2, and M3) with tool wt of -1.4-1.6  ×  10  e, and four 
small segments ($1, $2, $3, and $4) with mol wt of-0.6-0.9  ×  10  e. The outer 
capsid  consists  of three  polypeptides,  or1, ~3,  and  ~2  (9).  The  ~1  and  ~3 
polypeptides are derived from genome segments $1 and $4, respectively (10). In 
the nomenclature contained in this paper, we have assigned the ~2 polypeptide 
as being a  product of the M1 gene.  This assignment is based on migration  of 
dsRNA  segments  on  gel  systems  containing  Tris-glycine  buffers.  We  have 
found  that  what  we  are  defining  as  the  M1  segment  migrates  as  the  M2 
segment  in systems containing  Tris-acetate  buffers. Thus,  our assignment  of 
the ~2 capsid polypeptide to the M1 segment is identical to Joklik's assignment 
of the  p2  polypeptide to  the  M2  segment  (10).  There  are  three  serotypes of 
mammalian  reovirus (types 1,  2,  and 3) defined on the basis of neutralization 
antibodies (11). Using hybrid recombinant clones consisting ofgenome segments 
derived from type 1 or 2 reovirus mixed with genome segments derived from 
type 3 reovirus, we have determined the gene segregating with, and responsible 
for, neutralization  and type specificity of reovirus. The results below show that 
the $1 genome segment which codes for or1, the minor outer capsid polypeptide 
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(10),  is  the  genome  segment  responsible  for  type  specificity. 
polypeptide is the type-specific antigen. 
Thus  the  ~1 
Materials and Methods 
Cells.  Mouse  L  cells were  maintained  in  suspension  culture  in  Joklik's modified Eagle's 
minimal essential medium  (Grand  Island Biological Co.,  Grand  Island,  N.  Y.)  supplemented 
with  5%  fetal calf serum  (International  Biological Laboratories,  Inc.,  [IBL],  Rockville, Md.). 
Monkey  CV-1 cells were  maintained  in  monolayers  in  "improved" minimal essential  media 
supplemented with  zinc,  insulin,  and  Hepes buffer  (IMEMZO)  (IBL)  supplemented  with  10% 
fetal calf serum (IBL). 
Virus.  Reovirus type 1 (Lang strain), type 2 (Jones strain), and type 3 (Dearing strain) were 
the  same  as  previously described  (11). Hybrid recombinant clones were prepared by mixedly 
infecting  L  cells  with  equal  multiplicities of temperature-sensitive  (TS) mutants  of type  3 
reovirus (12) and clones derived from either type 1 or type 2. A large number of progeny clones 
were  collected at  39°C (a  nonpermissive temperature  for  the  TS  mutants)  and  shown  to  be 
recombinants. 2 Eight such clones were utilized in the present analysis (Fig. 1 and Table I). 
Neutralization Assay.  Antisera against the three reovirus serotypes were obtained from the 
National Institute of Allergy and Infectious Diseases,  Betheeda,  Md.,  catalog numbers V-701- 
511-570 (anti-l), V-702-501-570 (anti-2),  and V-703-501-570 (anti-3).  These antisera were prepared 
in  geese.  Approximately  100  plaque-forming  units  of the  three  serotypes  and  hybrids  were 
incubated with various dilutions of antisera for 45 rain at 37°C, then titored at 31°C, on L-cell 
monolayers as previously described (12). Greater than 80% reduction of plaques was considered 
neutralization of virus. 
Analysis of Viral RNA.  Analysis of viral RNA was performed as previously described (13). 
Briefly,  the  three  serotypes  of reovirus and  the  hybrid  clones  were  grown  at  31°C on  CV-1 
monolayers at a multiplicity of infection of 10 in 60  × 15 mm plastic Falcon tissue culture dishes 
(Falcon Plastics, Div. of BioQuest, Oxnard, Calif.) in 5 ml of IMEMZO.  At 2.5 h postinfection, 
media containing 0.25 mCi 32p was added and at 48 h, infected monolayers were washed with an 
isotonic buffer [0.14 M NaC1, 0.01 M Tris-hydrochloride (pH 7.4), 0.0015 M MgC12 (Buffer A)] and 
cells were collected.  The cells were treated  with 0.5% Nonidet P-40 in Buffer A,  nuclei were 
removed by  centrifugation,  and  RNA was precipitated at  -20°C  in  ethanol.  The precipitates 
were pelleted by high speed centrifugation, dried, dissolved in gel sample buffer, and applied to 
slab gels (10% acrylamide, 0.267% bis-acrylamide)  as described by Laemmli (14). After electropho- 
resis, gels were fixed and autoradiography performed. 
Results 
Migration Pattern of dsRNA Segments.  In Fig. 1 the migration patterns of 
dsRNA from reovirus types 1, 2, and 3 and from eight hybrid clones are shown, 
accompanied by  a  diagrammatic representation of these patterns.  It can be 
seen that the serotype of origin for each genome segment can be determined for 
the hybrid clones by comparison to the three serotypes. Clones A-F represent 
hybrid clones between  serotypes  1  and  3,  while  clones  G  and  H  represent 
hybrid clones between serotypes 2 and 3. For example, clone C contains L1, L3, 
and S1 segments from type 1 and the remainder of segments from type 3. The 
genome segment most easily distinguished is the S1 segment, which migrates 
much faster for types 1 and 2 than it does for type 3. We have been unable to 
repreducibly distinguish the $2 segment of type 1 from that of type 3, but the 
$2  segment of type 2  is  easily distinguishable from the homologous type 3 
segment (Fig.  1,  clones G  and H).  In terms of comparing the genome RNA 
patterns between types 2 and 3, it has previously been shown that the middle 
2  Sharpe, A. H., R. F. Ramig, T. A. Mustoe, and B. N. Fields.  A genetic  map of  reovirus.  I. 
Correlation  of  genome RNAs between serotypes 1, 2, and 3. Virology. In  press. FIG.  i.  (A)  Autoradiograms of  reovirus dsRNA segments from serotypes I,  2,  and 3 (I,  II, 
and III)  and  eight hybrid clones (A-H).  Clones A-F  represent  hybrid clones between 
serotypes 1 and 3, and clones G and H  represent hybrid clones  between serotypes 2 and 3. 
(B) Diagrammatic  representation  of the migration patterns shown  in Fig. 1  A. The  10 
dsRNA  segments  for reovirus consist of three large segments  (L1, L2, and L3), three 
medium  segments (M1, M2, and M3), and four small segments ($1,  $2, $3, and $4).  The 
segments from types 1  and 2 are represented by thick bars, and those from type 3 by thin 
bars. Dashed  lines ($2 segments  from clones  A-F)  represent  segments  that cannot be 
assigned to  either  type 1  or  type 3. 
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TABLE  I 
Neutralization of Hybrid Clones of Reovirus with Type-Specific Antibody 
Gene coding for:  Antibody titer* 
Nonstruc-  Neutraliza- 
Clone  Outer capsid  Core  Uncertain 
tural  1  2  3  tion type 
M1  S1  $4  L1  L2  $2  M3  $3  L3  M2 
A  1  1  3  3  1  3  3  1  1  1,280  -  20  1 
B  1  1  1  3  3  3  1  3  3  1,280  -  20  1 
C  3  1  3  1  3  -  3  3  1  3  1,280  -  <20  1 
D  1  1  1  1  3  1  1  1  1  1,280  -  20  1 
E  1  3  3  3  3  -  3  3  3  1  <20  -  160  3 
F  3  3  1  1  3  -  3  1  3  1  <20  -  160  3 
G  2  3  3  3  3  2  3  3  3  3  -  <20  160  3 
H  3  3  2  3  3  3  3  3  3  3  -  <20  160  3 
Number  of  times  3  0  4  3  3  1  3  3  1 
excluded 
* Reciprocal maximum antiserum dilution resulting in >80% plaque reduction. 
and small size class RNA segments of type 2 migrate in an order that does not 
correspond to the order of these segments in reovirus type 3. 2 Specifically, the 
M2 segment from type 2 migrates slower than the type 2 M1 segment and the 
$4  segment from type 2 migrates slower than the type 2 $3  segment. Thus, 
clone G  (Fig.  1)  contains a  type 3  M2  segment and  a  type 2 M1  segment; 
similarly, clone H (Fig.  1) contains a type 2 S4 segment and a type 3 $3 segment. 
Neutralization of Hybrid Clones by Type-Specific Antibody.  Antibody pre- 
pared against type 1 reovirus neutralized the homologous strain at a dilution of 
1:1,280 while showing no effect on type 3 at a serum dilution of 1:20. Antibody 
prepared against type 2 had a titer of 1:1,280 against type 2 and 1:20 against 
type 3. Type 3 antibody neutralized type 3 virus at a dilution of 1:160-320 while 
neutralizing type 1 or 2 at dilution of 1:20. 
When the hybrid clones were examined for neutralization by type-specific 
antibody, they all behaved as either type 1 or 3 (Table I). No clones behaved as 
type 2. The titer needed for neutralization of hybrid clones always corresponded 
to the titer needed to neutralize the parental reovirus serotypes; the titers were 
never intermediate. In every hybrid clone studied the type as determined by 
neutralization testing, correlated solely with the S1 gene product; i.e., when S1 
is derived from type 1 the hybrid is neutralized by type 1 antiserum while 
every clone containing S1 from type 3 is neutralized by type 3 antiserum. Both 
of the other outer capsid peptides (coded for by the M1 and $4 genome segments) 
did not correlate with the neutralization serotype in almost half the hybrids 
examined. In a similar manner, all of the other segments could be excluded as 
being responsible for type specificity. 
The type-specific immune sera  used in  these experiments do not  contain 
antibody  predominantly to  the  ~1  protein,  but  are  reactive  with  all  the 
structural polypeptides of the virion. This has been shown by direct immune 
precipitation  of all  viral  polypeptides at  dilutions  of antisera  from  1:20 to 
1:5,000 (T. A. Mustoe and B. N. Fields, unpublished observations). Thus, anti- 
bodies directed against the other two outer capsid proteins (¢r3 and/~2) do not 
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Discussion 
These  studies  demonstrate  the  feasibility  of using  a  genetic  approach  to 
define the biologic properties of a  virus. In this instance, we have shown that 
the S1 gene codes for the viral neutralization antigen, the ~1 polypeptide. As 
with  most  viruses,  the  reovirus  protein  responsible  for  neutralization  is  a 
capsid protein.  The ~1 polypeptide, despite its prominent biologic role as the 
neutralization antigen, represents only 1% of the virion's polypeptides and less 
than 2% of the total mass of the outer capsid (9).  The two major outer capsid 
proteins,  ~2 and or3 comprise 64% of the total virion and over 98% of the outer 
capsid  (9).  There  are  approximately  550  and  900  molecules of  ~2  and ~3, 
respectively, per virion but only 30 molecules of crl  (9).  Thus,  the relatively 
minor crl polypeptide must occupy a strategic position to be the sole determinant 
of type specificity and be the target of neutralizing antibody. When the outer 
shell of reovirus is progressively digested by chymotrypsin, ~3 is removed first, 
followed by ~2 and finally crl (15). It has been speculated that ~1 is associated 
with the ~2 core spikes that penetrate into the outer capsid shell of the intact 
virion. It is through these spikes that viral transcriptase may be activated and 
single-stranded  messenger  RNA  released  (16). Perhaps  binding  of the  ~1 
polypeptide  by  antibody prevents  this  crucial  event  in  viral  replication.  In 
addition,  binding of the ~1  polypeptide may interfere with adsorption of the 
virus into the cell or uncoating of the virus. 
One particularly significant advantage of this approach in determining the 
biologic properties of the individual virion components is that potential artifacts 
that  can  occur  by  chemical  extraction  of individual  viral  components  are 
avoided.  It  is  easy to  imagine that  the  chemical  extraction of polypeptides 
might alter the natural configuration of the protein or expose regions of the 
polypeptides that are normally hidden. Antibody produced to proteins isolated 
in  this  manner might  play  no  role  in  natural  infections.  This  approach  is 
currently being used to study other biologic properties of reovirus virions and 
viral-host interactions. We have recently found that the ~1 polypeptide is also 
the hemagglutinin polypeptide of reovirus (H.  Weiner, unpublished observa- 
tions). 
Summary 
The S1 genome segment of reovirus is linked to type specificity as determined 
by neutralization antibody. This gene segment codes for a  minor outer capsid 
polypeptide  (crl).  Therefore, ~1  is  the  peptide  responsible  for  induction  of 
neutralization antibody and confers type specificity. This biologic property of 
reovirus was defined using hybrid recombinants clones between reovirus types 
1 and 3 and 2 and 3. 
Note Added  in  Proof.  The dsRNA  segment designated as M1  in this publication 
(defined on the basis of migration in Tris-glycine  buffer systems) is  identical to  the 
dsRNA segment previously designated M2 (defined on the basis of migration in Tris-ace- 
tate buffer systems). To be consistent with the earlier designation, in future publications 
from our laboratory we will refer to this dsRNA as M2. 
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